05/20/22 7:00 AMNasdaq : BTAI low floatBioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment ConferenceBioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D.,RHEA-AIneutral
05/09/22 7:00 AMNasdaq : BTAI earningslow floatBioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational HighlightsReceived FDA approval of IGALMI™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults Top-line data readout in Q4 2022/early Q1 2023 for TRANQUILITY II Phase 3 trial evaluating BXCL501 in acute treatment of agitationRHEA-AIvery positive
05/05/22 7:00 AMNasdaq : BTAI conferenceslow floatBioXcel Therapeutics to Present at Three Upcoming Investor ConferencesBioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D.,RHEA-AIneutral
05/03/22 7:00 AMNasdaq : BTAI clinical triallow floatBioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s DiseaseBioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical companyRHEA-AIvery positive
04/26/22 7:00 AMNasdaq : BTAI conferencesearningslow floatBioXcel Therapeutics to Report First Quarter 2022 Financial Results on May 9, 2022BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence (AI) approaches to identify and develop transformative medicines in neuroscience and immuno-oncology, today announced thatRHEA-AIneutral
04/19/22 7:05 AMNasdaq : BTAI low floatBioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in OncologyOnkosXcel, a Company subsidiary, to utilize proprietary AI-powered platform to progress therapies to address difficult-to-treat cancers with high unmet need New structure to unlock growth opportunities and maximize value of neuroscience and immuno-oncology franchises Lead pipeline asset, BXCL701,RHEA-AIvery positive
04/19/22 7:00 AMNasdaq : BTAI low floatBioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment AuthorityBioXcel Therapeutics, Inc. (Nasdaq: BTAI) (the “Company” or “BioXcel Therapeutics”),RHEA-AIvery positive
04/06/22 7:00 AMNasdaq : BTAI fda approvallow floatBioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in AdultsFirst and only FDA-approved orally dissolving sublingual film for mild, moderate or severe agitation in patients with schizophrenia or bipolar I or II disorder 1 IGALMI demonstrated onset of action as early as 20 minutes and high response rate with both 120 mcg and 180 mcg doses in pivotal studiesRHEA-AIneutral
03/10/22 7:04 AMNasdaq : BTAI earningslow floatBioXcel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational HighlightsReady to launch BXCL501 upon approval as Company nears April 5, 2022 PDUFA action date Initiated TRANQUILITY II AND III pivotal Phase 3 trials for BXCL501 in acute treatment of agitation associated with Alzheimer’s disease Submitted IND to evaluate BXCL501 as adjunctive treatment for majorRHEA-AIpositive
03/09/22 7:00 AMNasdaq : BTAI conferenceslow floatBioXcel Therapeutics to Present at the Barclays Global Healthcare ConferenceBioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D.,RHEA-AIneutral